This article is more than 5 years old. Information may no longer be current.

International Liver Congress Offers Groundbreaking Data

With more than 10,000 attendees and a record-breaking number of presentation submissions, 2016’s International Liver Congress offered much support of our current knowledge of hepatitis C virus along with small, ground breaking studies in areas of need.

A study in kidney transplant patients produced showed very high cure rates and will open doors for increased use of HCV-positive organs in immunosuppressed patients. Another showed treating patients with decompensated cirrhosis could improve their status enough to be deactivated or delisted from the liver transplant waiting list. New data also emerged on pangenotypic regimens that produced sustained virologic response in a variety of patients with complications such as cirrhosis or resistance-associated variants.

Additionally, real-world studies continued to reflect the efficacy seen in clinical trials, across various countries and hepatic complications.

Read The Take Home for more details on these studies from Ira M. Jacobson, MD, Co-Chief Medical Editor of HCV Next, and three other experts.

Also of note, the leaders of four international societies —the American Association for the Study of Liver Diseases, European Association for the Study of the Liver, Asian Pacific Association for the Study of the Liver and Latin American Association for the Study of the Liver — signed the Joint Society Statement for Elimination of Viral Hepatitis during the Opening Ceremony. This dedication promises to bring more attention to the global efforts to cure HCV.

We look forward to further discussing how this eradication may be achieved.